Events Search and Views Navigation
Starts: Oct 5, 2018 8:30 AM (CET) Ends: Oct 7, 2018 1:00 PM (CET) 4th International Conference on MULTIPLE MYELOMA October 5-7, 2018 – Mandelieu, France Chairs: Kenneth C. Anderson, Maria Victoria Mateos, Philippe Moreau This meeting aims to bring to the forefront the latest data and information in the field of Multiple Myeloma, providing a unique opportunity for world class leaders in the field to debate vital and contentious issues in Myeloma. This thought-provoking academic dialogue will address the…Find out more »
Starts: Dec 8, 2018 7:00 AM (PT) Ends: Dec 12, 2018 1:00 PM (PT) The premier event in malignant and non-malignant hematology December 1-4, 2018 San Diego, CA See below for quick links to resources from the 2018 ASH Annual Meeting. Mark your calendar for the world’s most comprehensive hematology event of the year, the 60th ASH Annual Meeting and Exposition in sunny San Diego. The meeting will provide an invaluable educational experience and the opportunity to review thousands of…Find out more »
2020 IMF Patient & Family Webinar: Multiple Myeloma – New Treatments, Diversity, and Caregiver Support
Join the IMF Patient & Family Webinar. This free two-hour webinar features a panel discussion about the latest treatments, diversity and caregiver support led by IMF Chief Medical Officer Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen). IMF President, Founder, and CEO Susie Durie and IMF Vice President of Support Groups Robin Tuohy will lead a special segment dedicated to caregiver support.
Other panelists include Deepu Madduri, MD of Tisch Cancer Institute/Mount Sinai Hospital; Craig Emmitt Cole, MD of Michigan State University; and Beth Faiman PhD, MSN, APRN-BC, AOCN, FAAN of Cleveland Clinic Taussig Cancer Institute.Find out more »
6th World Congresses on Controversies in Multiple Myeloma (COMy)Find out more »
This meeting will bring together leading experts in multiple myeloma who will discuss the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussions.Find out more »